Want to see SE:PILA full AI Analyst Report?

PILA PHARMA AB (PILA) Price & Analysis

1 Followers

PILA Stock Chart & Stats

kr2.20

-kr0.50(-13.33%)

At close: Mar 06 4:00 PM EST

kr2.20

-kr0.50(-13.33%)

Day’s Range― - ―

52-Week Rangekr1.02 - kr3.30

Previous CloseN/A

Volume9.62K

Average Volume (3M)235.52K

Market Cap

kr58.24M

Enterprise Valuekr55.39

Total Cash (Recent Filing)kr15.90M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.32

Next Earnings

Aug 27, 2026

EPS Estimate

-0.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.46

Shares Outstanding45,682,120

10 Day Avg. Volume194,482

30 Day Avg. Volume235,519

Financial Highlights & Ratios

PEG Ratio-0.37

Price to Book (P/B)4.82

Price to Sales (P/S)63.25

P/FCF Ratio-7.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clean Balance Sheet / Zero DebtZero reported debt and a materially higher equity base in 2025 reduce insolvency risk and give management flexibility to fund R&D or negotiate partnerships. This durable capital-structure strength lowers refinancing and interest-rate exposure through development cycles.

Revenue Rebound And Growth TrendA demonstrated rebound in top-line activity and an overall positive revenue-growth metric suggest improving commercial or license activity. If sustained, this durable trend can validate programs, support partner interest, and reduce absolute funding needs over multiple quarters.

Focused R&D Pipeline On TRPA1 (metabolic Disease)A concentrated scientific focus on TRPA1 and metabolic diseases creates a clear development pathway and scientific differentiation. This specialization supports efficient trial design, partner appeal for licensing, and durable expertise-driven value creation if clinical results progress.

Bears Say

Persistent Cash BurnConsistent negative operating and free cash flow over multiple years indicates continued funding needs and dependency on equity or partner financing. This structural cash burn raises dilution and execution risk until programs can generate sustainable inflows or secure long-term partners.

Widening Net Losses And Negative MarginsGrowing operating losses and persistently negative margins erode equity and strain runway. Structurally, this means the business must either materially improve R&D efficiency, cut costs, or secure non-dilutive funding; otherwise cumulative losses will limit strategic options.

Very Small Organizational Scale / Execution RiskAn organization with a single employee implies heavy reliance on contractors, partners, or a key person. That creates durable execution and continuity risk for clinical programs, regulatory interactions, and commercial negotiations, potentially delaying milestones.

PILA FAQ

What was PILA PHARMA AB’s price range in the past 12 months?

PILA PHARMA AB lowest stock price was kr1.02 and its highest was kr3.30 in the past 12 months.

What is PILA PHARMA AB’s market cap?

PILA PHARMA AB’s market cap is kr58.24M.

When is PILA PHARMA AB’s upcoming earnings report date?

PILA PHARMA AB’s upcoming earnings report date is Aug 27, 2026 which is in 20 days.

How were PILA PHARMA AB’s earnings last quarter?

PILA PHARMA AB released its earnings results on Feb 26, 2026. The company reported -kr0.369 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is PILA PHARMA AB overvalued?

According to Wall Street analysts PILA PHARMA AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PILA PHARMA AB pay dividends?

PILA PHARMA AB does not currently pay dividends.

What is PILA PHARMA AB’s EPS estimate?

PILA PHARMA AB’s EPS estimate is -0.22.

How many shares outstanding does PILA PHARMA AB have?

PILA PHARMA AB has 45,682,120 shares outstanding.

What happened to PILA PHARMA AB’s price movement after its last earnings report?

PILA PHARMA AB reported an EPS of -kr0.369 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.83%.

Which hedge fund is a major shareholder of PILA PHARMA AB?

Currently, no hedge funds are holding shares in SE:PILA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PILA PHARMA AB

Based in Sweden, PILA PHARMA AB (publ) is a pharmaceutical firm actively engaged in clinical development. The company's principal drug, XEN-D0501, is a TRPV1 antagonist which has successfully completed two phase 2a clinical studies aimed at treating type 2 diabetes. PILA PHARMA AB (publ) was founded in 2014 and maintains its headquarters in Malmö, Sweden.